Warning Letter — Revlon Group Holdings, LLC
The FDA issued a Warning Letter to Revlon Group Holdings, LLC on June 2, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This action affects Revlon Group Holdings, LLC and its relevant departments responsible for regulatory compliance, manufacturing, and product labeling for items overseen by CDER.
The issuance of a Warning Letter by CDER indicates that the FDA has identified significant violations of regulatory requirements, which may involve manufacturing practices, product labeling, or unapproved drug claims. For a diversified personal care company, this suggests an enforcement focus on products that fall under the statutory definition of a drug, potentially requiring substantial remediation of quality systems or marketing materials.
Regulatory and Quality teams should conduct an immediate audit of product claims and manufacturing documentation for any products classified as drugs under FDA purview. Companies should verify that all OTC drug products meet current good manufacturing practice (CGMP) and appropriate marketing authorization requirements.
FDA Warning Letter issued to: Revlon Group Holdings, LLC. 06/02/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/revlon-group-holdings-llc-722596-06022026
Open in openFDA / FDA.gov